NewAmsterdam Pharma Company N.V. (NAMS) revenue

Revenue · fiscal 2025
$22.50M

NewAmsterdam Pharma Company N.V. (NAMS) reported revenue of $22.50M in fiscal 2025 (the year ended December 31, 2025). That is 50.6% lower than the $45.56M of fiscal 2024. Figures as of 18 Nov 2026, 09:52 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$22.50M
Change on fiscal 2024
−50.6%
Highest on record
$102.69Mfiscal 2022
Lowest on record
$14.09Mfiscal 2023
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

NewAmsterdam Pharma Company N.V. revenue, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $102.69M in fiscal 2022 and the lowest $14.09M in fiscal 2023.

History · 4 fiscal years

Revenue by fiscal year

NewAmsterdam Pharma Company N.V. revenue, year by year

NewAmsterdam Pharma Company N.V. (NAMS) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$22.50M 50.6% down
2024$45.56M 223.4% up
2023$14.09M 86.3% down
2022$102.69M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

More on NAMS

NewAmsterdam Pharma Company N.V., figure by figure

NewAmsterdam Pharma Company N.V. (NAMS) overview: price, valuation and scorecard

NewAmsterdam Pharma Company N.V. revenue: questions and answers

What is NewAmsterdam Pharma Company N.V.'s revenue?

NewAmsterdam Pharma Company N.V. (NAMS) reported revenue of $22.50M in fiscal 2025 (the year ended December 31, 2025). That is 50.6% lower than the $45.56M of fiscal 2024.

What are the highest and lowest revenue figures on record for NewAmsterdam Pharma Company N.V.?

Across the 4 fiscal years on record (2022–2025), the highest was $102.69M in fiscal 2022 and the lowest $14.09M in fiscal 2023.

How is NewAmsterdam Pharma Company N.V.'s revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For NewAmsterdam Pharma Company N.V. it is on record here for 4 fiscal years, 2022 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “NewAmsterdam Pharma Company N.V. (NAMS) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/NAMS/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.